OKYO PHARMA LTD SP.ADR/65 Total Assets
OKYO PHARMA LTD SP.ADR/65 total assets. Based on the latest financial reports, OKYO PHARMA LTD SP.ADR/65 (OK10) holds total assets worth €4.64 Million EUR (≈ $5.43 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see OK10 company net worth for the company's overall valuation and market capitalisation.
Total Assets of OKYO PHARMA LTD SP.ADR/65 (2022–2025)
Total assets of OKYO PHARMA LTD SP.ADR/65 from 2022 to 2025. This chart illustrates how OKYO PHARMA LTD SP.ADR/65's total assets have evolved over time, based on quarterly financial data. See OKYO PHARMA LTD SP.ADR/65 stock quote for real-time trading data and today's change.
OKYO PHARMA LTD SP.ADR/65 - Asset Composition Analysis
OKYO PHARMA LTD SP.ADR/65 Total Assets Breakdown (March 2025)
OKYO PHARMA LTD SP.ADR/65 total assets breakdown as of March 2025. OKYO PHARMA LTD SP.ADR/65's total assets of €4.64 Million consist of 99.9% current assets and 0.1% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 42.5% |
| Accounts Receivable | €0.00 | 0.0% |
| Inventory | €0.00 | 0.0% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €0.00 | 0.0% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2022–2025)
This chart illustrates how OKYO PHARMA LTD SP.ADR/65's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore OK10 working capital efficiency to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: OKYO PHARMA LTD SP.ADR/65's current assets represent 99.9% of total assets in 2025, an increase from 99.9% in 2022.
- Cash Position: Cash and equivalents constituted 42.5% of total assets in 2025, down from 62.8% in 2022.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2022.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
OKYO PHARMA LTD SP.ADR/65 Competitors by Total Assets
Key competitors of OKYO PHARMA LTD SP.ADR/65 based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
CSL LTD SPON.ADR 2
F:CSJA
|
Germany | €38.45 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578
|
China | CN¥8.59 Billion |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
PHARVARIS N.V. EO -12
F:9EN
|
Germany | €301.45 Million |
|
NANOBIOTIX S.A. SP.ADR
F:5NRA
|
Germany | €67.76 Million |
|
Chengdu Easton Biopharmaceuticals Co Ltd
SHG:688513
|
China | CN¥3.82 Billion |
OKYO PHARMA LTD SP.ADR/65 - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.58 | 0.28 | 0.28 |
| Quick Ratio | 0.58 | 0.28 | 0.28 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €-3.42 Million | €-7.23 Million | €-7.23 Million |
OKYO PHARMA LTD SP.ADR/65 - Advanced Valuation Insights
This section examines the relationship between OKYO PHARMA LTD SP.ADR/65's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 14.92 |
| Latest Market Cap to Assets Ratio | 10.44 |
| Asset Growth Rate (YoY) | 138.6% |
| Total Assets | €3.68 Million |
| Market Capitalization | $38.38 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values OKYO PHARMA LTD SP.ADR/65's assets at a significant premium (10.44x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: OKYO PHARMA LTD SP.ADR/65's assets grew by 138.6% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for OKYO PHARMA LTD SP.ADR/65 (2022–2025)
The table below shows the annual total assets of OKYO PHARMA LTD SP.ADR/65 from 2022 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-03-31 | €3.68 Million ≈ $4.30 Million |
+138.59% |
| 2024-03-31 | €1.54 Million ≈ $1.80 Million |
-70.38% |
| 2023-03-31 | €5.20 Million ≈ $6.08 Million |
+21.00% |
| 2022-03-31 | €4.30 Million ≈ $5.03 Million |
-- |
About OKYO PHARMA LTD SP.ADR/65
OKYO Pharma Limited, a clinical-stage biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptid… Read more